This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Alitair Pharmaceuticals, Inc.

Drug Names(s): erdosteine, ALT-09, ALT09

Description: Erdosteine is a thiol derivative developed to modulate mucus production and viscosity in addition to increasing mucociliary transport thereby improving expectoration. Erdosteine is also shown to exhibit inhibitory activity against the effects of free radicals.

Deal Structure: Edmond Pharma and Adams Respiratory Therapeutics
In May 2005, Adams Respiratory Therapeutics and Edmond Pharma announced that they have entered into an exclusive License and Supply Agreement under which Adams will develop and commercialize Edmond's erdosteine in the United States.

Adams Respiratory Therapeutics and Reckitt Benckiser
In December 2007, Adams Respiratory Therapeutics reported that they entered into an Agreement and Plan of Merger with Reckitt Benckiser. The Merger was effected as of January 29, 2008.

In July 2014, Reckitt Benckiser announced that it is pursuing a demerger of the RB Pharmaceuticals business with a separate UK listing. In December 2014, Reckitt Benckiser completed the demerger of the Reckitt Benckiser Pharmaceuticals business with a separate UK listing under the name of Indivior PLC.

Edmond Pharma and Alitair
In September 2013, Alitair and Edmond Pharma announced that they have entered into a definitive...See full deal structure in Biomedtracker

Partners: Edmond Pharma S.r.l. Indivior plc

Erdosteine News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug